I have a great job because every day I get to talk to smart people doing interesting work to make healthcare better. In February’s MedCity News Hangout, I spoke with four of those people about big data.
The conversation included a designer, a neuroscientist, an expert in consumer payments and a doctor. Each person brought a unique perspective and professional experience to the conversation, often from way outside healthcare. It was a perfect illustration of how we need everyone’s talents to make healthcare more efficient and people friendly.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Here are my favorite parts of the hangout. You can scroll down to admire the design of blood test results from WellnessFX.
If you want to know how working with masses of health data has affected each person’s own healthcare choices, jump to the 37:29 minute mark of the video.
Jeff French, head designer at WellnessFX, 1:07 to 7:25
“What we are going to be rolling out in the next couple months, on top of improved visualizations and interactive charts, is our own WellnessFX score. What we’re hoping to do with that is provide an even simpler, easier to understand piece of information that is attached to certain results to give people an idea of how they stack up both to previous test results as well as to other people and to really give a more standardized comparison point for how to improve their results, how to make sense of what the numbers mean and not just see the value of their test results, but get a better sense of is this something I need to improve significantly or is it OK as it is.”
Bob Ballou, CEO of Pay MD, 7:30 to 18:00
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Elizabeth Stringer, analyst at Axial Healthcare, 18:30 to 24:58
“We are building models to predict outcomes in pain treatment. We are looking at RX claims, medical claims, behavioral claims and eligibility. We wanted to identify where physicians are using best practices to treating the pain.
“What I’m extremely excited about is building models to predict best outcomes in pain treatment. We wanted to know, ‘Can we take data from the claims and predict who will do well or who will have a bad outcome on this opiod treatment?’
“Our next generation models will bring in what we call emerging data. We’ll be mining social media to help us build our models. We’re also building a patient app so they can tell us their pain level at any given time.”
Dr. Linda Girgis, primary care physician, 26:00 to 28:49
“We need to have comparisons and track tests over time. I’m going to use cholesterol as an example. If a patient comes in one time and their cholesterol is 270, we give them advice to change their lifestyle, diet and exercising. They come back to see us and their cholesterol is 220, we can show them the data to encourage them to change their lifestyle further. Or if it’s getting worse, we can make a case that they need to be on medication.
“With my patients who are diabetics, I try to get them to do their own blood sugars at home because they are the best at managing their diabetes. The patient is the best one to know how to make the adjustment to bring that data under control.”
